Key result
IVL in acute MI yields similar long-term mortality to non-MI cases.
Why the study?
Does intravascular lithotripsy provide safe and effective modification of calcified coronary lesions with comparable long-term outcomes in patients with acute MI versus non-MI?
Cohort (n=201)
No
Does intravascular lithotripsy provide safe and effective modification of calcified coronary lesions with comparable long-term outcomes in patients with acute MI versus non-MI?
Absolute Event Rate: 9% vs 8.1%
p-value: p=0.997
Intravascular lithotripsy is highly successful for calcified coronary lesions, yielding comparable long-term safety and clinical outcomes in patients presenting with acute MI versus non-MI.
BACKGROUND: Intravascular lithotripsy (IVL) utilizes high-energy sonic waves to create controlled fractures in calcified plaques, facilitating vessel preparation and improving stent apposition. METHODS: The study was designed to evaluate the safety and efficacy of IVL in a patient population that included individuals with acute myocardial infarction (MI). A total of 201 consecutive patients who underwent percutaneous coronary intervention (PCI) using IVL [Shockwave C2 or C2+ (Shockwave Medical Inc, Santa Clara, CA, US)] from April 2020 onward were included in this single-center registry. The study population comprised 76 patients with acute MI (Group 1) and 125 patients with non-MI (Group 2). RESULTS: Left ventricular ejection fraction was lower (46.0% ± 13.1% vs. 50.9% ± 10.5%; p = 0.022), while SYNTAX Score was significantly higher (20.0 ± 11.3 vs. 16.5 ± 10.2; p = 0.059) in Group 1 than in Group 2 (46.0% ± 13.1% vs. 50.9% ± 10.5%; p = 0.022). The overall IVL success rate and procedure success rate were very high (97.5% and 99.5%, respectively). A mean increase in lumen area was observed in Group 1 and Group 2: 5.9 ± 3.7 mm2 vs. 4.5 ± 2.2 mm2 and 237% vs. 239%, respectively. In the long-term follow-up there was no difference in all-cause mortality between Group 1 and Group 2 (9.0% vs. 8.1%; p = 0.997), cardiac death (p = 0.340), repeat MI (p = 0.986) and major adverse cardiovascular events [MACE; cardiac death, myocardial infarction, stroke] (16.8% vs. 9.8%; p = 0.501). Prior chronic kidney disease (CKD), post rota-atherectomy debulking, prior coronary artery bypass graft (CABG) and longer lesions were independent predictors of long-term all-cause mortality. CONCLUSIONS: Intravascular lithotripsy is an effective treatment for the modification of calcified atherosclerotic lesions, with a high success rate and few periprocedural complications. The long-term outcomes achieved in this complex population are satisfactory.
No takes yet. Share an insight, caveat, or question.
Oleksy et al. (2026) conducted a cohort in Calcified coronary lesions (n=201). Acute myocardial infarction vs. Non-myocardial infarction was evaluated on All-cause mortality (p=0.997). Among patients undergoing PCI with intravascular lithotripsy, long-term all-cause mortality did not differ significantly between those with acute MI and those without MI (9.0% vs. 8.1%; p=0.997).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: